Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 31, 2025EMBO Molecular MedicineOpen Access

SMAD7: riding on fibrosis-limiting routes and beyond

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLeonardo MartinGGGiulio GabbianiGMGuido R.Y. De Meyer

Discussion

Loading...

Member takes

Overview

Review highlights antifibrotic effects of SMAD7 in myofibroblasts, suggesting new therapeutic strategies for fibrosis.

Key Points

  • SMAD7 inhibits fibrosis by blocking TGF-β signaling, showing potential as a therapeutic target.
  • It specifically limits macrophage-driven fibrogenesis within myofibroblasts through paracrine mechanisms.
  • Integration of SMAD7 modulation into CAR-T cell therapies could enhance regenerative outcomes against fibrosis.
  • Understanding SMAD7 in cardiac and skeletal muscle tissues may reprogram fibrosis in chronic diseases.

Cite This Study

Martin et al. (2025) studied this question.

synapsesocial.com/papers/689a0c5fe6551bb0af8cf5f6https://doi.org/10.1038/s44321-025-00283-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fibroblast Smad7 Induction Protects the Remodeling Pressure-Overloaded Heart2024 · 47 citations
  2. 2Cardiomyocyte‐Specific Smad7 Protects the Pressure‐Overloaded Heart, Inhibiting the Transforming Growth Factor‐β Receptor 1/Smad2/3 Cascade2026
  3. 3Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts2007 · 83 citations
  4. 4The pivotal role of TGF-β/Smad pathway in fibrosis pathogenesis and treatment2025 · 70 citations
  5. 5Smad7 inhibits angiotensin II-induced hypertensive cardiac remodelling2013 · 70 citations